0000000000268917

AUTHOR

Marin Burlea

showing 2 related works from this author

Overview of the pediatric healthcare system in Romania.

2020

Until 1989, Romania was one of the countries of the communist bloc in Europe and its healthcare system was characterized by centralized planning and severe underfunding, with low performance and low quality healthcare. Since 1998, Romania replaced the Semashko model with a social health insurance system, highly centralized under the management of the Ministry of Health as the central administrative authority. After joining the European Union, quality of life increased in our country and there were efforts to improve the quality of healthcare, including pediatric and neonatal care. Still, Romania has the lowest share of health expenditure of gross domestic product among the European Union Me…

Economic growthReviewGross domestic product03 medical and health sciencesprimary care0302 clinical medicineQuality of life (healthcare)Health caremedia_common.cataloged_instanceMedicine030212 general & internal medicineSocial determinants of healthEuropean unionHuman resourcesChildrenmedia_commonbusiness.industryRomaniahealthcare systemInfant mortalityPediatrics Perinatology and Child Healthschool medicineProfessional associationbusinessmedical education030217 neurology & neurosurgeryTurk pediatri arsivi
researchProduct

Effects of prophylactic ibuprofen and paracetamol administration on the immunogenicity and reactogenicity of the 10-valent pneumococcal non-typeableH…

2016

ABSTRACT Prophylactic paracetamol administration impacts vaccine immune response; this study (www.clinicaltrials.gov: NCT01235949) is the first to assess PHiD-CV immunogenicity following prophylactic ibuprofen administration. In this phase IV, multicenter, open-label, randomized, controlled, non-inferiority study in Romania (November 2010–December 2012), healthy infants were randomized 3:3:3:1:1:1 to prophylactically receive immediate, delayed or no ibuprofen (IIBU, DIBU, NIBU) or paracetamol (IPARA, DPARA, NPARA) after each of 3 primary doses (PHiD-CV at age 3/4/5 months co-administered with DTPa-HBV-IPV/Hib at 3/5 and DTPa-IPV/Hib at 4 months) or booster dose (PHiD-CV and DTPa-HBV-IPV/Hib…

Malemedicine.medical_specialtyAntipyreticsparacetamolImmunologyIbuprofenBooster doseDiphtheria-Tetanus-acellular Pertussis Vaccinesmedicine.disease_causeGastroenterologyHaemophilus influenzaePneumococcal Vaccines03 medical and health sciences0302 clinical medicinevaccine030225 pediatricsInternal medicinemedicineHumansImmunology and Allergy030212 general & internal medicineAntipyretic10-valent pneumococcal conjugateAcetaminophenfeverPharmacologyReactogenicityRomaniabusiness.industryIncidenceorganic chemicalsImmunogenicityInfantIbuprofenResearch PapersAntibodies BacterialHealthy VolunteersAcetaminophenVaccinationTreatment OutcomeImmunologyFemaleprophylaxisbusinessmedicine.drugHuman Vaccines & Immunotherapeutics
researchProduct